AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24455828 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Glu-OC with iPTH, bALP, TRAP5
Number of subjects: 68
Study 22021142 — intervention group
Group type: EXPERIMENTAL
Intervention: PHILOS alone (Group A)
Number of subjects: 50
Study 22021142 — intervention group
Group type: EXPERIMENTAL
Intervention: PHILOS augmentation plus minimally invasive injectable graft (MIIG) X3 Hivisc (Group B)
Number of subjects: 50
Study 18723296 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin-based chemotherapy (Group 3)
Number of subjects: 422
Study 18723296 — intervention group
Group type: COMPARATOR
Intervention: Basic radiotherapy course alone (Group 1)
Number of subjects: 422
Study 18723296 — intervention group
Group type: COMPARATOR
Intervention: Additional boost of 5 Gy in 2 fractions (Group 2)
Number of subjects: 422
Study 18723296 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and concurrent chemotherapy
Number of subjects: 422
Study 18723296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to the cochlea
Number of subjects: 422
Study 16925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergoid immunotherapy
Number of subjects: 53
Study 16925684 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 53
Study 15503655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + simvastatin (Vytorin)
Number of subjects: 0
Study 11322745 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose at treatment endpoint = 0.05 mg/kg; mean total dose = 1.2 mg/day)
Number of subjects: 13
Study 11322745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9165504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose toremifene (200 or 240 mg/d)
Number of subjects: 733
Study 9165504 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 or 40 mg/d)
Number of subjects: 733
Study 8427853 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment groups
Number of subjects: 178
Study 8427853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 2887102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 3
Study 2887102 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 3
Study 2887102 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3
Study 29787858 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling plus nicotine replacement therapy (C + NRT)
Number of subjects: 278
Study 29787858 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation counseling (C)
Number of subjects: 278
Study 27504637 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART offered to all HIV-positive adults
Number of subjects: 12894
Study 27504637 — intervention group
Group type: COMPARATOR
Intervention: ART offered according to national guidelines (CD4 count ≤ 350 cells/μl)
Number of subjects: 12894
Study 27504637 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing
Number of subjects: 12894
Study 27504637 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care within 6 months
Number of subjects: 12894
Study 27504637 — intervention group
Group type: EXPERIMENTAL
Intervention: Community attitudes about ART
Number of subjects: 12894
Study 27504637 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated baseline HIV prevalence
Number of subjects: 12894
Study 25017577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh lutein-enriched egg-yolk beverage
Number of subjects: 100
Study 25017577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried version of the lutein-enriched egg-yolk beverage
Number of subjects: 100
Study 25017577 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage composed of the dried individual components
Number of subjects: 100
Study 25017577 — intervention group
Group type: COMPARATOR
Intervention: Plain control beverage
Number of subjects: 100
Study 22895351 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg/d propranolol for 12 months postburn
Number of subjects: 179
Study 22895351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 179
Study 20683279 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica montana
Number of subjects: 0
Study 20683279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17910332 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with Culex quinquefasciatus extract
Number of subjects: 40
Study 17910332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15088866 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection by location
Number of subjects: 0
Study 15088866 — intervention group
Group type: COMPARATOR
Intervention: Selection by color
Number of subjects: 0
Study 15088866 — intervention group
Group type: COMPARATOR
Intervention: Neutral letters
Number of subjects: 0
Study 11574763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol (mitoxantrone 7 mg/m² days 1/3/5, fludarabine 15 mg/m² every 12 h days 1-5, cytarabine as bolus infusion 1000 mg/m² over 1 h every 12 h days 1-5)
Number of subjects: 29
Study 11574763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol (cytarabine as continuous infusion 100-150 mg/m² over 24 h days 1-5)
Number of subjects: 29
Study 11574763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol
Number of subjects: 29
Study 9692704 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour topical method (bismuth, metronidazole, amoxycillin, pronase) after a 6-week course of ranitidine and omeprazole
Number of subjects: 80
Study 9692704 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (2 g/day) plus omeprazole (20 mg b.d.) for 2 weeks followed by a 4-week course of ranitidine
Number of subjects: 80
Study 7933682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP infusion at 0.16 mg/kg/min (group A)
Number of subjects: 172
Study 7933682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP infusion at 0.18 mg/kg/min (group B)
Number of subjects: 172
Study 7933682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (combined groups)
Number of subjects: 172
Study 7933682 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects from ATP infusion
Number of subjects: 172
Study 2965719 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 69
Study 2965719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 69
Study 2965719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31987724 — intervention group
Group type: COMPARATOR
Intervention: Control group from the Community Youth Development Study
Number of subjects: 2002
Study 29741564 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (36:9:19:4; n = 62)
Number of subjects: 190
Study 29741564 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (36:9:13:10; n = 66)
Number of subjects: 190
Study 29741564 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet (36:17:11:4; n = 64)
Number of subjects: 190
Study 27449150 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator
Number of subjects: 52
Study 27449150 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 52
Study 27449150 — intervention group
Group type: EXPERIMENTAL
Intervention: Real patients (post-simulation practice)
Number of subjects: 52
Study 27449150 — intervention group
Group type: COMPARATOR
Intervention: Post-simulation assessment scores
Number of subjects: 52
Study 24679061 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg per day)
Number of subjects: 10010
Study 24679061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10010
Study 22642525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive‐behavioral treatment (Unified Protocol for the Treatment of Emotional Disorders in Youth)
Number of subjects: 31
Study 20856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention (nurse-delivered adherence intervention)
Number of subjects: 15
Study 20856132 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 15
Study 20856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention
Number of subjects: 15
Study 18072016 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg)
Number of subjects: 72
Study 18072016 — intervention group
Group type: COMPARATOR
Intervention: simvastatin (40 mg)
Number of subjects: 72
Study 18072016 — intervention group
Group type: COMPARATOR
Intervention: combination of ezetimibe and simvastatin
Number of subjects: 72
Study 16579717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for insomnia
Number of subjects: 209
Study 16579717 — intervention group
Group type: COMPARATOR
Intervention: Primary care reference values
Number of subjects: 209
Study 15598784 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 mug/kg weekly for 4 weeks
Number of subjects: 39
Study 15598784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11700903 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable number/grammatical category relationship matched English
Number of subjects: 0
Study 11700903 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable number/grammatical category relationship opposite to English
Number of subjects: 0
Study 11700903 — intervention group
Group type: EXPERIMENTAL
Intervention: No relationship between syllable number and grammatical category
Number of subjects: 0
Study 9270645 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-dose aprotinin (1.0 x 10(6) KIU)
Number of subjects: 167
Study 9270645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2.7 +/- 0.5 x 10(6) KIU)
Number of subjects: 167
Study 9270645 — intervention group
Group type: COMPARATOR
Intervention: Control (no aprotinin treatment)
Number of subjects: 167
Study 8173929 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 849
Study 8173929 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated patients
Number of subjects: 849
Study 8173929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (irradiated and non-irradiated)
Number of subjects: 849
Study 3130221 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 240
Study 3130221 — intervention group
Group type: COMPARATOR
Intervention: NORPLANT-2 implants
Number of subjects: 240
Study 3130221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NORPLANT and NORPLANT-2 implants
Number of subjects: 240
Study 31600749 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (β2MG and MCP-1)
Number of subjects: 302
Study 31600749 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 302
Study 28522646 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 39
Study 28522646 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 39
Study 25510450 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer network intervention including peer mediation and direct instruction
Number of subjects: 95
Study 25510450 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 95
Study 23694782 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 2437
Study 23694782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2437
Study 22111972 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 27
Study 19471286 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0
Study 19471286 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents
Number of subjects: 0
Study 16644323 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels < 100 pg/mL
Number of subjects: 601
Study 16644323 — intervention group
Group type: COMPARATOR
Intervention: BNP levels >= 100 pg/mL
Number of subjects: 601
Study 12475575 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (0.4‐0.8 mg/h)
Number of subjects: 50
Study 12475575 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fenoterol (60 ‐ 120 microg/h)
Number of subjects: 50
Study 10849527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CT) - Cycle 1: cytarabine 200 mg/m2/day (days 1-7) and idarubicin 12 mg/m2/day (days 1-2)
Number of subjects: 19
Study 10849527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CT) - Cycle 2: cytarabine 2000 mg/m2/day (days 1-6) and amsacrine 120 mg/m2/day (days 1-3)
Number of subjects: 19
Study 10849527 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSCT eligibility after CT
Number of subjects: 19
Study 10849527 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha maintenance
Number of subjects: 19
Study 10849527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic examination of bone marrow
Number of subjects: 19
Study 9377317 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (Extracapsular Cataract Extraction)
Number of subjects: 64
Study 9377317 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 64
Study 9377317 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 64
Study 8473644 — intervention group
Group type: COMPARATOR
Intervention: No aspirin for > or = 10 days and no heparin (n = 12)
Number of subjects: 57
Study 8473644 — intervention group
Group type: COMPARATOR
Intervention: No aspirin for > or = 10 days but heparin, 10,000 IU, at the time of catheterization (n = 5)
Number of subjects: 57
Study 8473644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day, for at least 5 days (n = 11)
Number of subjects: 57
Study 8473644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 75 mg/day for > or = 5 days before angioplasty (n = 11)
Number of subjects: 57
Study 8473644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day for > or = 3 days before angioplasty (n = 9)
Number of subjects: 57
Study 8473644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day for > or = 3 days before angioplasty followed by 1,000 mg during angioplasty (n = 9)
Number of subjects: 57
Study 2951806 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms
Number of subjects: 12
Study 2951806 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms
Number of subjects: 12
Study 2951806 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31663831 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 636
Study 31663831 — intervention group
Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis plus mechanical thrombectomy (MT)
Number of subjects: 636
Study 31847977 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: papain 2% or 4% topical therapy, Unna boot compression therapy in phase 2
Number of subjects: 28
Study 31847977 — intervention group
Group type: COMPARATOR
Intervention: Group B: 2% hydrogel topical therapy, cellulose membrane followed by Unna boot compression therapy in phase 2
Number of subjects: 28
Study 31847977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received single-layer elastic compression therapy (SurePress; ConvaTec) and educational activities, exercises, leg elevation, oral nutrition supplementation, and ulcer cleaning
Number of subjects: 28
Study 27845510 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrode resection loop (group A)
Number of subjects: 100
Study 27845510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrode resection loop (group B)
Number of subjects: 100
Study 27845510 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 100
Study 25515123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric-acoustic stimulation (EAS)
Number of subjects: 22
Study 25515123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cochlear implants (CI)
Number of subjects: 22
Study 25515123 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing control group
Number of subjects: 22
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3‐ANCA levels in relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3‐ANCA levels in non-relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of PR3‐ANCA from remission to peak in relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3‐ANCA values at entry in relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak PR3‐ANCA values in relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to reach peak PR3‐ANCA values in relapsing patients
Number of subjects: 28
Study 23380137 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to reach peak PR3‐ANCA values in non-relapsing patients
Number of subjects: 28
Study 21318582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3252
Study 21318582 — intervention group
Group type: COMPARATOR
Intervention: Moderately reduced GFR
Number of subjects: 3252
Study 20027453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish (G1)
Number of subjects: 15
Study 20027453 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaF + 6% CaF(2) varnish (G2)
Number of subjects: 15
Study 17867479 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Hydroxypropyl Methylcellulose (HPMC)
Number of subjects: 100
Study 17867479 — intervention group
Group type: COMPARATOR
Intervention: 1% Sodium Hyaluronate (NaHa)
Number of subjects: 100
Study 17867479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 14741244 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise at 60% VO(2peak) after caffeine ingestion
Number of subjects: 16
Study 14741244 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise at 60% VO(2peak) after placebo ingestion
Number of subjects: 16
Study 14741244 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest after caffeine ingestion
Number of subjects: 16
Study 14741244 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest after placebo ingestion
Number of subjects: 16
Study 11502917 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, then 10 mg/day thereafter)
Number of subjects: 431
Study 11502917 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 431
Study 11502917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 11502917 — intervention group
Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 431
Study 9745423 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (starting dose, 10 +/- 0.3 micrograms/kg per day; mean treatment dose, 4 +/- 2 micrograms/kg per day)
Number of subjects: 40
Study 9745423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8150348 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin, isoniazid, and ethambutol
Number of subjects: 130
Study 8150348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 3179642 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA (0.1-0.2 mmol/kg body weight)
Number of subjects: 20
Study 31986989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg
Number of subjects: 144
Study 31986989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg
Number of subjects: 144
Study 31986989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 31986989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (both doses)
Number of subjects: 144
Study 31196844 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ+MTX
Number of subjects: 426
Study 31196844 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ
Number of subjects: 426
Study 31196844 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-based strategies
Number of subjects: 426
Study 31196844 — intervention group
Group type: COMPARATOR
Intervention: MTX+pred
Number of subjects: 426
Study 28073779 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion (2 pmol·kg‐1·min‐1)
Number of subjects: 23
Study 28073779 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 23
Study 26721003 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 70
Study 26721003 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Primary Closure (DPC)
Number of subjects: 70
Study 22332898 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine outcome monitoring (ROM) instruments for mental health assessment
Number of subjects: 1302
Study 22332898 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 1302
Study 21079955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyanoacrylate applied every 3 to 5 days for 3 months
Number of subjects: 0
Study 21079955 — intervention group
Group type: COMPARATOR
Intervention: Topical silicone gel applied twice a day for 3 months
Number of subjects: 0
Study 19778479 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG-primed cycles (Group B)
Number of subjects: 400
Study 19778479 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-primed cycles (Group C)
Number of subjects: 400
Study 19778479 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH plus HCG-primed cycles (Group D)
Number of subjects: 400
Study 19778479 — intervention group
Group type: COMPARATOR
Intervention: Non-primed cycles (Group A)
Number of subjects: 400
Study 16824559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubbles method (revealing small parts of the face)
Number of subjects: 18